Connect with us

Business

Omnicell Showcases Latest Advancements to Medication Management Portfolio at Arab Health Exhibition and Congress

Published

on

News Of Emirates – Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced the Company will be showcasing the latest advancements to its medication management portfolio at the Arab Health Exhibition and Congress from 27-30 January in Dubai. Arab Health is the largest gathering of healthcare and trade professionals in the Middle East region.

According to a report by Colliers International, healthcare spending in Saudi Arabia alone has grown at a compound annual growth rate of 12.1 percent over the last nine years, and is expected to increase to US$160 billion by 2030. Omnicell’s solution portfolio supports the vision of autonomous pharmacy, a roadmap designed to improve patient outcomes and operational efficiencies while helping to reduce cost through a series of autonomous and digital workflows, powered by a cloud data platform.

The autonomous pharmacy vision integrates solutions across three key areas. These will be showcased in Hall 3, Stand J30 during the Exhibition and Congress:

  • Automation – innovative solutions designed to digitize and streamline workflows across the continuum of care. Omnicell’s platform of automation solutions supports medication safety on patient wards; provides more efficient medication storage, dispensing, and filling in the hospital pharmacy; and helps improve medication adherence through automated multimed packaging solutions for outpatient pharmacy, which can result in better patient outcomes.
  • Intelligence – predictive intelligence that provides actionable insights to better understand medication usage and improve pharmacy supply chain management. Omnicell solutions offer flexibility to manage supplies anywhere in the hospital through enhanced tracking, usage capture and visibility to help reduce stock outs or over-ordering inventory.
  • Expert Services – an extension of pharmacy operations to support improved efficiency and enhanced patient care. These services can help deliver an accelerated time-to-value for implementation projects and greater achievement of anticipated outcomes.

“At Omnicell, we recognize the risk and cost associated with manual, inefficient processes,” said Arthur Van Dongen, vice president and general manager, International at Omnicell. “We are committed to delivering the technology and tools that will automate these processes, ultimately helping our hospital partners achieve their operational, financial, and clinical outcomes.”

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and expert services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 6,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 40,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell’s innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

GSMA Statement on Coronavirus

Published

on

News Of Emirates – The GSMA is monitoring and assessing the potential impact of the Coronavirus on its MWC20 events held annually in Barcelona, Shanghai and Los Angeles and as well as the Mobile 360 Series of regional conferences. The upcoming MWC Barcelona event, 24-27 February 2020, will proceed as planned, across all venues at Fira Gran Via and Fira Montjuïc, including YoMo and Four Years From Now (4YFN). Specifically, for MWC Barcelona 2020, several measures are already in place, and updates can be found on www.mwcbarcelona.com/about/news/.

The GSMA will:

  • Carefully follow and adhere to: the World Health Organisation’s (WHO) recommendations, all applicable Chinese government recommendations, all Spanish health authority recommendations and all police/health recommendations and protocols
  • Provide additional medical personnel for on-site support in the run-up to and during the event
  • Work with Fira de Barcelona to ensure sufficient sanitising products throughout all venues and implement other activity in line with recommendations from our city partners
  • Support exhibitors who may not be able to travel to MWC Barcelona (via GSMA account managers or the Customer Care Team).

The GSMA confirms that there have been no registration impacts on MWC Barcelona thus far and further updates will be issued as advice develops. However, we strongly urge exhibitors and attendees to implement appropriate guidelines and protocols as suggested by the WHO and other health authorities to contain and mitigate against any further spread of the virus. Currently, the WHO has decided not to declare a global public health emergency, saying it was still too early for such a move and has advised that, ‘measures to limit the risk of exportation or importation of the disease should be implemented, without unnecessary restrictions of international traffic’. Up-to-date WHO advice can be found here: www.who.int/ith/2020-27-01-outbreak-of-Pneumonia-caused-by-new-coronavirus/en/ and the most recent press release issued by WHO is here:https://www.who.int/news-room/detail/28-01-2020-who-china-leaders-discuss-next-steps-in-battle-against-coronavirus-outbreak.

Continue Reading

Business

Merz Aesthetics Presents Data at the IMCAS World Congress 2020

Published

on

News Of Emirates – Merz, a global leader in medical aesthetics, announced today that data on the Merz Aesthetics product portfolio, including Belotero®, Cellfina® and Radiesse® will be featured in oral and poster presentations at the 2020 International Master Course on Aging Science (IMCAS) World Congress, to be held from 30 January to 1 February 2020 in Paris, France. 

“This meeting provides a platform for Merz Aesthetics to not only foster education and continuous training but also, to engage in thoughtful industry conversations while connecting with medical aesthetics physicians and fellow industry leaders from around the world,” said Bob Rhatigan, CEO of Merz Aesthetics. “We are grateful that our heritage and innovation in this space allows us to partner with world-renowned medical aesthetic experts, to share research on the diversified Merz Aesthetics product portfolio at the IMCAS World Congress.” 

In addition to the poster presentations listed below, Merz Aesthetics is sponsoring the symposium event “Facial Rejuvenation: Interactive Sessions to Level-Up Your Injection Skills”, to be held on Saturday, 1 February at 10.30h – 12.30h, Room Amphi Bleu. The session will be opened by Bob Rhatigan, CEO of Merz Aesthetics and will include treatment insights from four international expert speakers: 

  • Dr. Tatjana Pavicic – Dermatologist, Germany 
  • Dr. Kate Goldie – Aesthetic Physician, United Kingdom 
  • Prof. Yana Yutskovskaya – Dermatologist, Russia 
  • Dr. Jani van Loghem – Aesthetic Physician, Netherlands 

Oral Presentations 

Independent presentations including data on the Merz Aesthetics portfolio: 

What’s new in minimally invasive treatments 

  • Update on dermal fillers (99921) – Kate Goldie, MBChB – UK. Thursday, 30 January, 17.54 – 18.06h, Amphi Bleu – Level 2 

Body shaping and cellulite 

  • Cellulite and skin laxity (93276). Doris Hexsel, Dermatologist – Brazil. Thursday, 30 January, 10.30 – 10.42h, Amphi Bleu – Level 2 
  • Cellulite treatment update: how dimples, laxity and volume can be effectively treated (98147)1. Gabriela Casabona, MD– Spain. Thursday, 30 January, 11.18 – 11.30h, Amphi Bleu – Level 2 

Biostimulatory fillers 

  • Biostimulators: how dilution/diffusion interferes with outcome (93391). Gabriela Casabona, MD – Spain. Saturday, 1 February, 16.30 – 16.42, Room 143 – Level 1 

E-Poster Presentations 

E-Posters will be available for viewing at the Poster Zone on Level 2, from Thursday, 30 January to Saturday, 1 February 2020

  • Distribution of cohesive polydensified matrix cross-linked hyaluronic acid volumizing gel in ex vivo human skin model. Christina Wollenburg, Jeanette Simon, Dr. Kay Marquardt, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany. 
  • Calcium hydroxylapatite microspheres provide organization into unorganized collagen networks leading to improvement of skin attractiveness. Gabriela Casabona, MD – Spain. Dr. Bartosch Nowag, Daniela Schäfer, Davide Greco, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany. 

BOCOUTURE® Milestone 

This year, Merz is also celebrating the ten-year anniversary of BOCOUTURE® (incobotulinumtoxin A) in Europe. The botulinum toxin is part of the Merz Aesthetics portfolio and has received approval in 15 countries in Europe within the last ten years. A Booth Talk about “BOCOUTURE® – 10 Years of a Unique Neurotoxin” with Dr. Thomas Rappl will take place Friday, 31 January, 16.00, Booth N° P251

Copyright © 2019 Merz Pharma GmbH & Co. KGaA. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KgaA. 

About Merz 

Merz is a global, diversified healthcare company based in Frankfurt, Germany. Privately-held for more than 111 years, the company operates in the areas of aesthetics, therapeutics and consumer care and is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In fiscal year 2018/19, Merz generated revenue of EUR 1,094 million; the company has a total workforce of 3,213 employees worldwide and a direct presence in 28 countries.

Continue Reading

Business

Kioxia Appoints Nobuo Hayasaka as President and CEO

Published

on

News Of Emirates – Kioxia Holdings Corporation today announced that the Board of Directors has appointed Nobuo Hayasaka as President and CEO of Kioxia, effective immediately. Dr. Hayasaka has served as Acting President and CEO since July 12, 2019, during Former President and CEO Yasuo Naruke’s medical leave of absence.

Dr. Naruke notified the company’s Board of Directors of his desire to step down as President, CEO and member of the board as he continues to focus on his health.

“Dr. Naruke has been an outstanding leader for our company over many years, and we thank him for the invaluable contribution he has made to shaping us into the company we are today.” said Stacy J. Smith, Executive Chairman of Kioxia. “This year presents an exciting opportunity for Kioxia, and President Hayasaka has the skills, experience and the full backing of our Board of Directors, management and employees as we move toward a new era of memory. I look forward to working closely with President Hayasaka and the rest of the executive team to ensure Kioxia’s ongoing success and value creation.”

“I am honored to be given the opportunity to serve as President and CEO of Kioxia. I am aware of the tremendous responsibility and look forward to continuing to work closely with our senior leadership team and employees to grow the company,” said Nobuo Hayasaka. “In order to maintain our position as a market leader in the new era of memory, we will continue to develop our core memory technology, while also investing in new ideas and innovations. We are committed to creating “value” through “memory,” which is what our company name implies, and developing new ways to contribute to the betterment of society.”

Dr. Hayasaka first joined Toshiba Corporation in 1984 after receiving a Ph.D in Electronic Engineering from Tohoku University. He was promoted to the position of Chief Technology Executive of Semiconductor and Storage Company in 2013 and held the role of Executive Officer, Corporate Vice President in 2014. Following Toshiba Memory’s separation from Toshiba Corporation, he was appointed as Executive Vice President, Executive Officer and Chief Technology Officer. He was appointed Acting President and CEO in July 2019.

About Kioxia

Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with memory by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia’s innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers.

Continue Reading

Trending

Copyright © 2019 News of Emirates